Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections
07. Februar 2022 02:15 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of...
Photodisinfection technology could be a game-changer in fight against antimicrobial resistance
21. Januar 2022 05:00 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant...
Ondine Biomedical appoints Charles Young to lead sales and marketing activity in North America
05. Januar 2022 11:01 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. (LON:OBI) has appointed Charles Young as its VP Sales & Marketing, North America to lead the commercialization of its...
Ondine Biomedical appoints Professor Trevor Jones to lead COVID-19 advisory board
15. Dezember 2021 05:00 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AIM listed life sciences company, Ondine Biomedical, has appointed Professor Trevor Jones CBE FMedSci to lead a new advisory board on the use of...
Ondine Receives Innovation Award of Excellence at World-leading Infection Conference, ICPIC 2021 for Photodisinfection Efficacy Results against COVID-19 Virus Variants including Delta
22. September 2021 05:00 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Ondine’s nasal photodisinfection technology has been shown to eliminate the RNA signature of SARS-CoV-2, including the dominant Delta variant,...
Preventing COVID-19 with Photodisinfection – New Results Presented at European Society of Photobiology
18. September 2021 01:27 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Nasal decolonization is recommended by the WHO and CDC to reduce hospital acquired infections (HAIs), [1] which have been exacerbated by COVID....
Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology
03. August 2021 06:00 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Ondine's technology platform is capable of painlessly and rapidly destroying a broad spectrum of bacteria, fungi, and viruses — including...
Ondine Biomedical Demonstrates Rapid Elimination of Bacterium Causing Flesh-Eating Disease
07. Mai 2020 12:48 ET
|
Ondine Biomedical Inc.
Vancouver, BC, Canada, May 07, 2020 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc., the global leader in Photodisinfection based therapies for multidrug resistant infection treatment and prevention,...
Ondine Biomedical Receives CE Mark for its Steriwave™ Nasal Photodisinfection Therapy
04. Mai 2020 19:59 ET
|
Ondine Biomedical Inc.
Vancouver, Canada, May 04, 2020 (GLOBE NEWSWIRE) -- Vancouver-based Ondine Biomedical Inc., the global leader in photodisinfection technology, announces it has received CE mark approval for its...